Physician profile
Theodore Chung
NPI 1306307301
$4,534.02
in general payments reported to CMS, 2019-2025
14 companies · $3,855 in 2025
The $3,855 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.72 · 2021: $33.41 · 2022: $92.15 · 2023: $145 · 2024: $326 · 2025: $3,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Travel and Lodging: $1,710 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.57 |
| Travel and Lodging | $1,709.61 |
| Education | $269.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,792.16 | 2024-2025 | Ensite, Ensite Precision |
| Biotronik INC. | $151.86 | 2025 | |
| Heartflow, INC. | $144.92 | 2023 | Ffrct |
| Medtronic, INC. | $109.35 | 2024 | Corevalve Evolut R |
| Lantheus Medical Imaging, INC. | $92.15 | 2022 | |
| United Therapeutics Corporation | $53.78 | 2025 | Tyvaso |
| Pfizer INC. | $38.99 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $38.72 | 2020 | |
| Abiomed | $24.18 | 2025 | |
| Genzyme Corporation | $21.23 | 2021 | |
| Scpharmaceuticals INC. | $17.22 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.19 | 2020 | |
| Merck Sharp & Dohme LLC | $16.34 | 2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.93 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.